Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry

被引:22
|
作者
Skierlo, S. [1 ]
Rommer, P. S. [1 ,2 ]
Zettl, U. K. [1 ]
机构
[1] Univ Rostock, Dept Neurol, Rostock, Germany
[2] Med Univ Vienna, Dept Neurol, Vienna, Austria
来源
ACTA NEUROLOGICA SCANDINAVICA | 2017年 / 135卷 / 04期
关键词
demyelinating diseases; disability; multiple sclerosis; symptomatic treatment; spasticity; QUALITY-OF-LIFE; PREVALENCE; EPIDEMIOLOGY; SPASTICITY; FATIGUE; NARCOMS; UPDATE; TRIAL;
D O I
10.1111/ane.12612
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To analyze symptomatic treatment in patients with multiple sclerosis ( MS). Background: Multiple sclerosis is a chronic inflammatory disease of the central nervous system, with accumulating disability symptoms like spasticity, voiding disorders, depression, and pain might occur. Material and methods: The nationwide German MS registry was initiated 2001 under guidance of the German MS society (Deutsche MS Gesellschaft). This study was performed as an interim analysis to lay foundation for future work on this topic. A subcohort of 5113 patients was assessed for this interim analysis. The mean age of the patients was 45.3 years; mean EDSS was 4.2. More than two-third of the enrolled patients were females (70.9%). Results: Most frequent symptoms were fatigue (60%), followed by spasticity (52.5%) and voiding disorders (51.7%). The likelihood of treatment was highest for epileptic disorders (68.8%), spasticity (68.5%), pain (60.7%), and depression (58.9%). Multivariate regression analysis showed that retirement was the strongest factor predictive for antispastic treatment (beta=. 061, P=. 005). Conclusion: Almost all patients in this analysis suffer from symptoms due to advanced MS. Treatment for the various symptoms differed tremendously. The likelihood of treatment correlated with the availability of effective therapeutic agents. Clinicians should put more awareness on MS symptoms. Symptomatic treatment may improve quality of life.
引用
收藏
页码:394 / 399
页数:6
相关论文
共 50 条
  • [41] The symptomatic management of multiple sclerosis
    Schapiro, Randall T.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2009, 12 (04) : 291 - 295
  • [42] Symptomatic uveitis and multiple sclerosis
    Mari, Y
    Gout, O
    Brézin, A
    Bakouche, P
    Lyon-Caen, O
    NEUROLOGY, 1999, 52 (06) : A133 - A133
  • [43] Symptomatic Management in Multiple Sclerosis
    Samkoff, Lawrence M.
    Goodman, Andrew D.
    NEUROLOGIC CLINICS, 2011, 29 (02) : 449 - +
  • [44] Symptomatic therapy in multiple sclerosis
    Giovanni Luigi Mancardi
    Neurological Sciences, 2006, 27 : s287 - s287
  • [45] Multiple sclerosis: Symptomatic therapies
    Metz, L
    SEMINARS IN NEUROLOGY, 1998, 18 (03) : 389 - 395
  • [46] Multiple sclerosis: symptomatic management
    Bitsch, A
    NERVENHEILKUNDE, 2000, 19 (06) : 316 - 319
  • [47] Symptomatic therapy in multiple sclerosis
    Mancardi, Giovanni Luigi
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 4) : S287 - S287
  • [48] Symptomatic therapies of multiple sclerosis
    Metz, LM
    Patten, SB
    McGowan, D
    BIOMEDICINE & PHARMACOTHERAPY, 1999, 53 (08) : 371 - 379
  • [49] Symptomatic uveitis and multiple sclerosis
    Edwards, L. J.
    Dua, H.
    Constantinescu, C. S.
    NEURO-OPHTHALMOLOGY, 2008, 32 (02) : 49 - 54
  • [50] Symptomatic management in multiple sclerosis
    Shah, Pushkar
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2015, 18 : S35 - S42